Figure 7
From: The atypical cyclin CNTD2 promotes colon cancer cell proliferation and migration
CNTD2 as a drug target candidate in CRC. LoVo cells were transfected with scrambled (Sc) RNA (10 nM) or with two different CNTD2-targeting siRNA (1 and 2) at 5 and 10 nM. (a) Down-regulation of CNTD2 mRNA was monitored by RT-qPCR. Columns represent the mean ± SEM of at least 4 experiments. *P < 0.05 vs scrambled, Mann-Whitney test. (b) LoVo cell number was determined by counting at the indicated time points after transfection. Values represent the mean ± SEM of at least four independent experiments performed in triplicates. *P < 0.05, **P < 0.01, ***P < 0.001 vs 10 nM, #P < 0.05, ##P < 0.01 vs 5 nM, Mann-Whitney test. Results are expressed as a percentage of control. (c) CNTD2 gene expression in different tissues according to the GTEXPortal (https://www.gtexportal.org/home/).
